Welcome to our dedicated page for Quince Therapeutics SEC filings (Ticker: QNCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Quince Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Quince Therapeutics's regulatory disclosures and financial reporting.
Quince Therapeutics director Christopher J. Senner reported a grant of 21,810 stock options on January 2, 2026. The derivative award is a director stock option with a $3.00 exercise price and an expiration date of January 2, 2036, covering 21,810 shares of common stock. Following this grant, he beneficially owns 21,810 derivative securities directly.
The options will vest in equal quarterly installments over a one-year period. Senner elected to receive these options in lieu of the annual director cash retainer for 2026 under the company’s Outside Director Compensation Policy.
Quince Therapeutics director Margaret McLoughlin reported receiving a new stock option award. On 01/02/2026, she was granted a Director Stock Option (Right to Buy) covering 19,547 shares of common stock at an exercise price of $3 per share. The filing shows this as an acquisition of derivative securities held directly.
According to the footnote, the option vests in equal quarterly installments over a one-year period. McLoughlin elected to receive this stock option grant in lieu of the 2026 annual director cash retainer under the company’s Outside Director Compensation Policy, meaning this award represents her director compensation rather than an open-market transaction.
Quince Therapeutics director David Lamond reported receiving a grant of 29,423 director stock options on January 2, 2026. The options have an exercise price of $3.00 per share and relate to Quince common stock, with 29,423 derivative securities beneficially owned after the transaction. According to the filing, these options were granted in lieu of Lamond’s 2026 annual director cash retainer under the company’s Outside Director Compensation Policy and will vest in equal quarterly installments over a one-year period. The transaction is reported as a directly held derivative security.
Quince Therapeutics director June Bray received a new stock option grant. On 01/02/2026, Bray was granted director stock options covering 18,724 common shares at an exercise price of $3 per share, with no cash paid for the options themselves.
The options vest in equal quarterly installments over a one-year period, meaning the grant is tied to ongoing board service during 2026. Bray elected to receive this option award in lieu of the annual director cash retainer for 2026 under Quince Therapeutics' Outside Director Compensation Policy. Following this grant, Bray beneficially owns 18,724 derivative securities directly.
Quince Therapeutics, Inc. insider Dirk Thye, who serves as director and as CEO and CMO, reported a transfer of common shares dated 12/10/2025.
The reported transaction with code G involved 739,885 common shares at a stated price of $0, moving from direct to indirect beneficial ownership through the Thye Trust. After this transaction, Thye held 255,000 common shares directly and 739,885 common shares indirectly via the Thye Trust.
Quince Therapeutics reported third‑quarter results and disclosed “substantial doubt” about its ability to continue as a going concern. The company posted a Q3 net loss of $13.4 million and a nine‑month net loss of $44.5 million.
Cash, cash equivalents, and short‑term investments were $26.3 million as of September 30, 2025. Quince raised additional capital through an ATM program (net $4.3 million YTD) and a June 2025 private placement that issued common stock, pre‑funded warrants, and common warrants for gross proceeds of $11.5 million.
The balance sheet shows a $17.5 million current portion of the EIB loan (fair value) due August 2026, $61.2 million in long‑term contingent consideration tied to the EryDel acquisition, and $14.9 million warrant liabilities. Stockholders’ equity was $1.1 million. Shares outstanding were 55,681,490 as of November 6, 2025.
Quince Therapeutics, Inc. filed a current report to note that it has announced its financial results for the quarter ended September 30, 2025 and shared recent business highlights. The company states that these details are contained in a press release dated November 12, 2025, which is furnished as Exhibit 99.1 to this report rather than being fully included in the body of the document.
Quince Therapeutics (QNCX) filed an 8-K under Regulation FD to correct an Investor Day statement. The company removed Slide 57 and the related video from its October 2, 2025 Virtual Investor Day and advised investors not to rely on the slide’s claim that IntraBio’s N-acetyl-L-leucine (NALL) “failed Phase 2 A-T study across all endpoints.”
Quince clarified its statement drew from a European Journal of Paediatric Neurology article describing a single-site study in ataxia-telangiectasia, which reported no significant improvements in ataxia symptoms or motor function, and was not the multi-site IntraBio Phase 2 Study.
Quince Therapeutics (QNCX) filed a prospectus supplement for an at‑the‑market offering of up to $75,000,000 of common stock under its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC.
As of this supplement, the company has sold 4,823,859 shares for $6,496,274 in gross proceeds, leaving $68,503,726 available for future sales under the program. The company states it is currently no longer subject to the offering limits of General Instruction I.B.6. of Form S-3; if it becomes subject again, it will file another supplement.
QNCX common stock trades on Nasdaq under “QNCX.” The closing price was $1.93 on October 16, 2025.
Quince Therapeutics, Inc. reports an amendment to its unsecured credit facility with the European Investment Bank. For the period from January 1, 2026 to March 31, 2026, the company’s required minimum cash balance under the EIB Facility will be reduced from EUR 14,650,000 to EUR 5,000,000, temporarily easing its cash covenant. During this same period, out of the overall 9% Deferred Interest Rate on Tranche A and Tranche B, 1% will be converted into a Fixed Rate to be paid on March 31, 2026 on those tranches. The full amendment will be filed as an exhibit to the company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2025.